CompletedNCT00246259
Long-acting risperidone or oral antipsychotics for early psychosis
About this title
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
Read the official source — NCT00246259Medication studyAges 18–30CanadaSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 30 years.
- Listed locations
- Calgary and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 77
- Sponsor
- Janssen-Ortho Inc., Canada
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- From 18 Years to 30 Years
- Official registry ID
- NCT00246259
- Official title
Show the full official title
An Open-Label Randomized Trial Comparing Risperdal Consta With Oral Antipsychotic Care in the Treatment of Early Psychosis
Get this study by email
Recruitment & locations
CompletedCalgary · Edmonton · Victoria
8 more locations
- Dartmouth
- Greater Sudbury
- Kingston
- London
- Markham
- Montreal
- Québec
- Verdun
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Ortho Inc., Canada.
Did this study involve medication?
Yes. The study involved medication, including Risperidone long-acting injection (LAI) and Oral Antipsychotic.
Who was this study for?
Listed age limits: 18 years to 30 years.
